Dynamic analysis of ocular fundus changes after different doses of bevacizumab in the treatment of retinopathy of prematurity in threshold perio

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100043345

Enrollment

Unknown

Registered

2021-02-11

Start date

2016-10-01

Completion date

Unknown

Last updated

2021-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

retinopathy of prematurity

Interventions

1.25mg group:vitreous injection with 1.25mg Bevacizumab

0.75mg group:vitreous injection with 0.75mg Bevacizumab

0.5mg group: vitreous injection with 0.5mg Bevacizumab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Infants with threshold ROP diagnosed in our hospital, the gestational age was 26-34 weeks.

Exclusion criteria

Exclusion criteria: 1. Clinically diagnosed as ROP, but did not reach the threshold period; 2. Infants with vital signs that not suitable for surgery.

Design outcomes

Primary

Measure	Time frame
the changes of fundus;	—

Countries

China

Contacts

Public ContactFeng Chen

Ethics Committee for Drug Research of Guangzhou Women and Children's' Medical Center

eyeguangzhou@126.com+86 13380064686

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026